Exklusiver Live-Stream direkt von der World of Trading - 2 Tage mit einzigartigen Themen und Experten. Kostenlos teilnehmen + Videos erhalten. -w-
13.08.2013 23:56:00

DNA Sequencing 2013: Market Developments, Growth Areas and Opportunities

NEW YORK, Aug. 13, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

DNA Sequencing 2013: Market Developments, Growth Areas and Opportunities
http://www.reportlinker.com/p01204594/DNA-Sequencing-2013-Market-Developments-Growth-Areas-and-Opportunities.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics

Summary: This market analysis was carried out to provide business information to developers, manufacturers and suppliers in the DNA sequencing field. Its findings include:

- Marketing and sales opportunities
- End-user purchasing decisions
- Market growth and shrinkage
- Innovation and new product opportunities
This study was conducted through specialist groups of experienced DNA sequencing end-users and its findings are therefore based on 'real world' market data.

Market Analysis and Opportunities

A competitive market analysis of current practices and future developments across 25 key market areas in the DNA sequencing field. Examples include:
- DNA Sequencing Techniques: Which DNA sequencing techniques are the market leaders and what changes do end-users predict over the next three years. Which DNA sequencing techniques are growing and which are reducing?
- DNA Sequencing Applications: Which DNA sequencing applications are the market leaders and what changes do end-users predict over the next three years. Which DNA sequencing applications are growing and which are reducing?
- Suppliers: Who are the major company suppliers in the DNA sequencing field and who do DNA sequencing end-users plan to purchase from over the next three years. Who are the top ten suppliers in this field, and what changes are predicted in three years from now.
- Opportunities: The findings of this study are analysed to identify opportunities to suppliers in the DNA sequencing field, in the 'Market Areas' indicated below.

Overview

DNA sequencing is important in all areas of biological research and increasing demand for this technique is driving advances in this field, in the form of next-generation techniques. Today, laboratories use a number of different sequencing methods, however common goals include increasing throughputs and speeds, while reducing costs.
Biopharm Reports has carried out a global market study of the DNA sequencing field, involving the participation of 233 DNA sequencers and decision-makers in more than 50 countries. This study was carried out to investigate market developments, and to identify new insights and opportunities to developers and vendors in this field.
This market study investigated current and future techniques and applications, end-users' plans for using DNA sequencing over the next three years, as well as preferred products, purchasing and new developments. Other market areas included new and emerging applications, end-users' principal sequencing systems and their strengths and weaknesses, current and future budgets, budget breakdown, consumables, challenges, innovation, software and sample preparation.

Further details of this study are summarised below:

Market Areas

- Routine use: Use of flow cytometry DNA sequencing by end-users for routine (developed and validated) DNA sequencing tests, the development or validation of DNA sequencing tests and for qualitative discovery using DNA sequencing methods.
- Companies: End-users purchases/use of DNA sequencing systems from more than 30 companies and their anticipated use of these systems by end-users over the next three years, each ranked according to their competitive position
- DNA sequencing techniques: Current use of more than 15 DNA sequencing techniques by end-users and their anticipated use of these techniques over the next three years, each ranked according to their competitive position.
- DNA sequencing applications: Current use of more than 12 DNA applications by end-users and their anticipated use of these applications over the next three years, each ranked according to their competitive position.
- Preferred Company: End-users' preferred Company supplier in the DNA sequencing field, each ranked according to their competitive position.
- Preferred Product: End-users' preferred product in the DNA sequencing field, each ranked according to their competitive position.
- Strengths: End-users' disclosures of the strengths of their preferred product in the DNA sequencing field, each ranked according to their competitive position.
- Weaknesses: End-users' disclosures of the weaknesses of their preferred product in the DNA sequencing field, each ranked according to their competitive
- Annual Financial Budgets: End-users' annual financial budgets for DNA sequencing studies.
- Budget Breakdown: The breakdown of end-users' current DNA sequencing financial budgets in eight key areas and their anticipated budget breakdown in these areas over the next three years.
- Future Financial Budgets: End-users' anticipated financial budget changes (percentage increases or decrease) over the next three years, relating to their DNA sequencing activities
- Consumables: End-users' top consumables, associated with their DNA sequencing activities.
- Quality Control Guidelines: End-users' adherence to quality control guidelines or procedures, relating to the conduct of DNA sequencing studies.
- Current Challenges: End-users' disclosures on molecular types that present the greatest technical challenges to DNA sequencing analysis, together with the associated sample types (matrices), associated DNA sequencing methods and the underlying reasons.
- Required Innovation: End-users' disclosures relating to 12 key areas of required innovation in the DNA sequencing field, each ranked (on a scale of 1 to 10) according to their importance.
- Recent Innovations: End-users disclosures on the most important innovations relating to their use of DNA sequencing, over the last three years.
- Future Innovation: End-users' disclosures on what they anticipate will be the most important innovations in the DNA sequencing, over the next three years.
- Biomarkers: End-users' application of DNA sequencing methods for the study of disease biomarkers, namely molecular types and their clinical utilities.
- Organisations: End-users organisations include clinics or hospitals, government bodies, large international companies, research institutes, small and medium sized companies, universities and veterinary centres.

- Fields: End-users professional fields include biotechnology, chemicals, clinical or hospital, defence, energy, environmental, food and drink, forensics, geology, government, healthcare, natural products, pharmaceuticals, research institutes, security and universities.
- Therapeutic Areas: End-users' DNA sequencing activities in terms of their general therapeutic area (20 different areas covered), including the main diseases with which their work is concerned.
- Bioinformatics software: End-users' disclosures on their preferred bioinformatics software, associated with DNA sequencing studies.
- Purpose: End-users' underlying reasons for using DNA sequencing analysis across 17 major fields (biotechnology, chemicals, clinical or hospital, defence, diagnostics (medical), energy, environmental, food and drink, forensics, geology, government, healthcare, natural products, pharmaceuticals, research institutes, security, university), each ranked according to their relative importance.
- Study Samples: Study sample types analysed by end-users using DNA sequencing methods, each ranked according to their relative importance.
- Sample Preparation: The use of sample preparation methods by end-users for DNA sequencing studies, each ranked according to their importance.

Executive Summary

Chapter 1 Introduction

Chapter 2 Study Participants

2.1 This Chapter
2.2 Countries
2.3 Regions
2.4 Organisation Types
2.5 Fields
2.6 DNA Sequencing Activities
2.7 Participants
2.8 Discussion

Figure 2.1 Countries of individuals who participated in DNA Sequencing 2012/13
Figure 2.2 Global regions of individuals who participated in DNA Sequencing 2012/13.
Figure 2.3 Organisation types of individuals who participated in DNA Sequencing 2012/13
Figure 2.4 Fields of individuals who participated in DNA Sequencing 2012/13
Table 2.1 Countries of individuals who participated in DNA Sequencing 2012/13
Table 2.2 Global regions of individuals who participated in DNA Sequencing 2012/13
Table 2.3 Organisation types of individuals who participated in DNA Sequencing 2012/13

Chapter 3 DNA Sequencing Techniques

3.1 This Chapter
3.2 Current Techniques
3.3 Future Techniques
3.4 Discussion

Figure 3.1 Top ten currently used DNA Sequencing techniques, indicated by individuals who participated in DNA Sequencing 2012/13
Table 3.1 Currently used DNA Sequencing techniques, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 3.2 Other currently used DNA Sequencing techniques, indicated by individuals who participated in DNA Sequencing 2012/13
Table 3.2 Other currently used DNA Sequencing techniques, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 3.3 Top ten DNA Sequencing techniques that end-users anticipate they will be using over the next three years (2012/13 to 2015/2016), indicated by individuals who participated in DNA Sequencing 2012/13
Table 3.3 DNA Sequencing techniques that end-users anticipate they will be using over the next three years (2012/13 to 2015/2016), indicated by individuals who participated in DNA Sequencing 2012/13
Figure 3.4 Other DNA Sequencing techniques that end-users anticipate they will be using over the next three years (2012/13 to 2015/2016), indicated by individuals who participated in DNA Sequencing 2012/13
Table 3.4 Other DNA Sequencing techniques that end-users anticipate they will be using over the next three years (2012/13 to 2015/2016), indicated by individuals who participated DNA Sequencing 2012/13

Chapter 4 DNA Sequencing Applications

4.1 This Chapter
4.2 Current Applications
4.3 Future Applications
4.4 Discussion

Figure 4.1 Top ten currently used DNA Sequencing applications, indicated by individuals who participated in DNA Sequencing 2012/13
Table 4.1 Currently used DNA Sequencing applications, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 4.2 Other currently used DNA Sequencing applications, indicated by individuals who participated in DNA Sequencing 2012/13
Table 4.2 Other currently used DNA Sequencing applications, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 4.3 Top ten DNA Sequencing applications that end-users anticipate they will be using over the next three years (2012/13 to 2015/2016), indicated by individuals who participated in DNA Sequencing 2012/13
Table 4.3 DNA Sequencing applications that end-users anticipate they will be using over the next three years (2012/13 to 2015/2016), indicated by individuals who participated in DNA Sequencing 2012/13
Figure 4.4 Other DNA Sequencing applications that end-users anticipate they will be using over the next three years (2012/13 to 2015/2016), indicated by individuals who participated in DNA Sequencing 2012/13
Table 4.4 Other DNA Sequencing applications that end-users anticipate they will be using over the next three years (2012/13 to 2015/2016), indicated by individuals who participated in DNA Sequencing 2012/13

Chapter 5 Companies

5.1 This Chapter
5.2 Current Companies
5.3 Future Companies
5.4 Discussion

Figure 5.1 Top ten DNA Sequencing company suppliers, currently used by individuals who participated in DNA Sequencing 2012/13
Table 5.1 DNA Sequencing company suppliers, currently used by individuals who participated in DNA Sequencing 2012/13
Figure 5.2 Other DNA Sequencing company suppliers, currently used by individuals who participated in DNA Sequencing 2012/13
Table 5.2 Other DNA Sequencing company suppliers, currently used by individuals who participated in DNA Sequencing 2012/13
Figure 5.3 Top ten DNA Sequencing company suppliers that end-users anticipate they will be using over the next three years (2012/13 to 2015/2016), indicated by individuals who participated in DNA Sequencing 2012/13
Table 5.3 DNA Sequencing company suppliers that end-users anticipate they will be using over the next three years (2012/13 to 2015/2016), indicated by individuals who participated in DNA Sequencing 2012/13
Figure 5.4 Other DNA Sequencing company suppliers that end-users anticipate they will be using over the next three years (2012/13 to 2015/2016), indicated by individuals who participated in DNA Sequencing 2012/13
Table 5.4 Other DNA Sequencing company suppliers that end-users anticipate they will be using over the next three years (2012/13 to 2015/2016), indicated by individuals who participated in DNA Sequencing 2012/13

Chapter 6 Preferred Companies and Products

6.1 This Chapter
6.2 Preferred Companies
6.3 Preferred products
6.4 Strengths
6.5 Weaknesses
6.6 Discussion

Figure 6.1 Top ten preferred suppliers in the DNA Sequencing field, indicated by individuals who participated in DNA Sequencing 2012/13
Table 6.1 Preferred suppliers in the DNA Sequencing field, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 6.2 Other preferred suppliers in the DNA Sequencing field, indicated by individuals who participated in DNA Sequencing 2012/13
Table 6.2 Other preferred suppliers in the DNA Sequencing field, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 6.3 Top ten preferred products in the DNA Sequencing field, indicated by individuals who participated in DNA Sequencing 2012/13
Table 6.3 Preferred products in the DNA Sequencing field, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 6.4 Other preferred products in the DNA Sequencing field, indicated by individuals who participated in DNA Sequencing 2012/13
Table 6.4 Other Top preferred products in the DNA Sequencing field, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 6.5 Top ten strengths of preferred products in the DNA Sequencing field, indicated by individuals who participated in DNA Sequencing 2012/13
Table 6.5 Strengths of preferred products in the DNA Sequencing field, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 6.6 Other strengths of preferred products in the DNA Sequencing field, indicated by individuals who participated in DNA Sequencing 2012/13
Table 6.6 Other strengths of preferred products in the DNA Sequencing field, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 6.7 Top ten weaknesses of preferred products in the DNA Sequencing field, indicated by individuals who participated in DNA Sequencing 2012/13
Table 6.7 Weaknesses of preferred products in the DNA Sequencing field, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 6.8 Other weaknesses of preferred products in the DNA Sequencing field, indicated by individuals who participated in DNA Sequencing 2012/13
Table 6.8 Other weaknesses of preferred products in the DNA Sequencing field, indicated by individuals who participated in DNA Sequencing 2012/13

Chapter 7 DNA Sequencing Expenditure and Budgets

7.1 This Chapter
7.2 Current Financial budget
7.3 Future Expenditure
7.4 Future General Budget

Figure 7.1 Annual financial budgets for DNA Sequencing studies, indicated by individuals who participated in DNA Sequencing 2012/13
Table 7.1 Annual financial budgets for DNA Sequencing studies, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 7.2 The breakdown of current financial budgets for DNA Sequencing studies, indicated by individuals who participated in DNA Sequencing 2012/13
Table 7.2 The breakdown of current financial budgets for DNA Sequencing studies, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 7.3 The anticipated future breakdown of financial budgets (over the next three years, 2012/13 to 2015/2016) for DNA Sequencing studies, indicated by individuals who participated in DNA Sequencing 2012/13
Table 7.3 The anticipated future breakdown of financial budgets (over the next three years, 2012/13 to 2015/2016) for DNA Sequencing studies, indicated by individuals who participated in DNA Sequencing 2012/13

Chapter 8 Purpose of DNA Sequencing Use

8.1 This Chapter
8.2 Purpose
8.3 Discussion

Figure 8.1 Top ten reasons for using DNA Sequencing in the biotechnology industry, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 8.2 Top ten reasons for using DNA Sequencing in clinics or hospitals, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 8.3 Top ten reasons for using DNA Sequencing in the environmental industry, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 8.4 Top ten reasons for using DNA Sequencing in the food and drink industry, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 8.5 Top ten reasons for using DNA Sequencing in the environmental industry, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 8.6 Top ten reasons for using DNA Sequencing in the Government organisations, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 8.7 Top ten reasons for using DNA Sequencing in the healthcare industry, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 8.8 Top ten reasons for using DNA Sequencing in the pharmaceutical industry, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 8.9 Top ten reasons for using DNA Sequencing in research institutes, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 8.10 Top ten reasons for using DNA Sequencing in universities, indicated by individuals who participated in DNA Sequencing 2012/13

Chapter 9 Samples

9.1 This Chapter
9.2 Samples
9.3 Discussion

Figure 9.1 Top ten sample types analysed using DNA Sequencing, indicated by individuals who participated in DNA Sequencing 2012/13
Table 9.1 Sample types analysed using DNA Sequencing, indicated by individuals who participated in DNA Sequencing 2012/13

Chapter 10 Sample Preparation

10.1 This Chapter
10.2 Sample Preparation
10.3 Discussion

Figure 10.1 Top sample preparation methods of DNA Sequencing users who participated in DNA Sequencing 2012/13
Table 10.1 Sample preparation methods of DNA Sequencing users who participated in DNA Sequencing 2012/13
Figure 10.2 Other sample preparation methods of DNA Sequencing users who participated in DNA Sequencing 2012/13
Table 10.2 Other sample preparation methods of DNA Sequencing users who participated in DNA Sequencing 2012/13

Chapter 11 Therapeutic Areas

11.1 This Chapter
11.2 Therapeutic Areas
11.3 Discussion

Figure 11.1 Top ten therapeutic areas of DNA Sequencing users who participated in DNA Sequencing 2012/13
Table 11.1 Therapeutic areas of DNA Sequencing users who participated in DNA Sequencing 2012/13
Figure 11.2 Other therapeutic areas of DNA Sequencing users who participated in DNA Sequencing 2012/13
Table 11.2 Other therapeutic areas of DNA Sequencing users who participated in DNA Sequencing 2012/13

Chapter 12 Disease Biomarkers

12.1 This Chapter
12.2 Use of DNA Sequencing
12.3 Biomarker Types
12.4 Clinical Utility
12.5 Discussion

Figure 12.1 The use of DNA Sequencing for the study of disease biomarkers, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 12.2 Principal disease biomarkers studied using DNA Sequencing, indicated by individuals who participated in DNA Sequencing 2012/13
Table 12.1 Other disease biomarkers studied using DNA Sequencing, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 12.3 Clinical utilities of disease biomarkers studied using DNA Sequencing, indicated by individuals who participated in DNA Sequencing 2012/13
Table 12.2 Other clinical utilities of disease biomarkers studied using DNA Sequencing, indicated by individuals who participated in DNA Sequencing 2012/13

Chapter 13 Bioinformatics Software

13.1 This Chapter
13.2 Bioinformatics Software
13.3 Discussion

Figure 13.1 Top ten bioinformatics software system used for DNA Sequencing, indicated by users who participated in DNA Sequencing 2012/13
Table 13.1 Bioinformatics software system used for DNA DNA Sequencing, indicated by users who participated in DNA Sequencing 2012/13
Figure 13.2 Other bioinformatics software system used for DNA Sequencing, indicated by users who participated in DNA Sequencing 2012/13
Table 13.2 Other bioinformatics software system used for DNA Sequencing, indicated by users who participated in DNA Sequencing 2012/13

Chapter 14 Challenging Applications

14.1 This Chapter
14.2 Most challenging Molecules
14.3 Most challenging sample types (matrices)
14.4 DNA Sequencing methods used
14.5 Underlying reasons
14.6 Discussion

Figure 14.1 The most challenging molecules studies using DNA Sequencing, indicated by users who participated in DNA Sequencing 2012/13
Table 14.1 The most challenging molecules studies using DNA Sequencing, indicated by users who participated in DNA Sequencing 2012/13
Figure 14.2 The most challenging sample types (matrices) studies using DNA Sequencing, indicated by users who participated in DNA Sequencing 2012/13
Table 14.2 The most challenging sample types (matrices) studies using DNA Sequencing, indicated by users who participated in DNA Sequencing 2012/13
Figure 14.3 Top ten DNA Sequencings methods used with the most challenging molecules studies using DNA Sequencing, indicated by users who participated in DNA Sequencing 2012/13
Table 14.3 DNA Sequencings methods used with the most challenging molecules studies using DNA Sequencing, indicated by users who participated in DNA Sequencing 2012/13
Figure 14.4 Top ten underlying reasons for the challenges encountered using DNA Sequencing analysis, indicated by users who participated in DNA Sequencing 2012/13
Table 14.4 Underlying reasons for the challenges encountered using DNA Sequencing analysis, indicated by users who participated in DNA Sequencing 2012/13

Chapter 15 Innovation

15.1 This Chapter
15.2 Required Innovation
15.3 Recent Innovation
15.4 Future Innovation
15.5 Discussion

Figure 15.1 Top ten most required areas of innovation in DNA Sequencing, indicated by individuals who participated in DNA Sequencing 2012/13
Table 15.1 Most required areas of innovation in DNA Sequencing, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 15.2 Other required areas of innovation in DNA Sequencing, indicated by individuals who participated in DNA Sequencing 2012/13
Table 15.2 Other required areas of innovation in DNA Sequencing, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 15.3 Top ten recent innovations (in the last three years) in DNA Sequencing, indicated by individuals who participated in DNA Sequencing 2012/13
Table 15.3 Recent innovations (in the last three years) in DNA Sequencing, indicated by individuals who participated in DNA Sequencing 2012/13
Figure 15.4 Top ten future anticipated innovations (in the next three years) in DNA Sequencing, indicated by individuals who participated in DNA Sequencing 2012/13
Table 15.4 Future anticipated innovations (in the next three years) in DNA Sequencing, indicated by individuals who participated in DNA Sequencing 2012/13

Chapter 16 Quality Control

16.1 This Chapter
16.2 Quality Control
16.3 Future Innovation
16.4 Discussion

Figure 16.1 Top ten most commonly used quality control guidelines or procedures used in DNA Sequencing analysis, indicated by individuals who participated in DNA Sequencing 2012/13
Table 16.1 Quality control guidelines or procedures used in DNA Sequencing analysis, indicated by individuals who participated in DNA Sequencing 2012/13

Chapter 17 DNA Sequencing Consumables

Chapter 18 Discussion

Chapter 19 Appendices

To order this report:
Genomics Industry:
DNA Sequencing 2013: Market Developments, Growth Areas and Opportunities


Contact Clare: clare@reportlinker.com  
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!